Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 21,000 shares at $2.50 ($53K) on 2026-06-12, disclosed to the SEC on 2026-06-16.
CEO Amit Kumar purchased 21,000 shares for $52,500, marking the largest purchase of his career. This significant insider buying comes as the stock trades near its 52-week low, potentially signaling confidence in the company's clinical pipeline.
The stock is down 24.53% over the past year and sits 48.14% below its 52-week high of $5.4566, though it is currently trading just 5.2% above its 52-week low of $2.69.
The trade itself is a catalyst as it represents the largest purchase of CEO Amit Kumar's career. The company views 2026 as a 'pivotal year' for advancing a breast cancer vaccine and ovarian CAR-T therapy, with updates on Phase II vaccine plans and CAR-T survival signals expected at a conference on April 15, 2026.
The company faces execution risk regarding its clinical pipeline and a negative forward P/E of -8.0 indicates current losses. Additionally, the stock carries a short interest of 3.19% and recent news highlights a 'very modest' cash burn, raising concerns about liquidity.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-09-11 | $14K | — | Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |